Wells Fargo & Company Benitec Biopharma Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.19 - $0.36 $1 - $3	9 Added 4.66%	202 $0
Q1 2023 May 12, 2023	BUY	$0.18 - $0.36 $0 - $0	2 Added 1.05%	193 $0
Q4 2022 Feb 13, 2023	BUY	$0.13 - $5.95 $18 - $827	139 Added 267.31%	191 $0
Q3 2022 Nov 14, 2022	BUY	$0.31 - $6.32 $1 - $31	5 Added 10.64%	52 $0
Q2 2022 Aug 12, 2022	BUY	$0.74 - $2.29 $2 - $9	4 Added 9.3%	47 $0
Q4 2021 Feb 14, 2022	BUY	$2.62 - $3.77 $5 - $7	2 Added 4.88%	43 $0
Q3 2021 Nov 15, 2021	SELL	$3.49 - $4.26 $24 - $29	-7 Reduced 14.58%	41 $0
Q2 2021 Aug 16, 2021	BUY	$3.94 - $5.81 $78 - $116	20 Added 71.43%	48 $0
Q1 2021 May 13, 2021	BUY	$2.59 - $9.26 $2 - $9	1 Added 3.7%	28 $0
Q4 2020 Feb 09, 2021	BUY	$2.61 - $4.79 $54 - $100	21 Added 350.0%	27 $0
Q3 2020 Nov 05, 2020	BUY	$5.66 - $8.7 $33 - $52	6 New	6 $0

1.42M

Ticker BNTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,809,500
Market Cap $280M
Description
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.